camptothecin has been researched along with Carcinoma, Renal Cell in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Matsunaga, T; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Tsujino, T; Uchimoto, T; Yoshikawa, Y | 1 |
| Cohn, A; Crowell, T; Figlin, R; Haas, NB; Harris, WB; Hussain, A; Hutson, T; Keam, B; Lee, JL; Li, J; Motzer, RJ; Randall, JM; Rha, SY; Richey, S; Senderowicz, A; Shaffer, D; Stone, E; Vaishampayan, U; Vogelzang, N; Voss, MH | 1 |
| Ashcroft, M; Carroll, VA; Moumen, A; Nathawat, K; Selvarajah, J | 1 |
| Cen, P; Rowe, J | 1 |
| Ciconte, J; Cohen, RB; Eliasof, S; Garmey, EG; Gunnarsson, O; Haas, NB; Heitjan, D; Hennessy, M; Hoffman-Censits, J; Jayaraman, L; Keefe, SM; Mamtani, R; Nixon, A; Piscitelli, A; Senderowicz, A; Smith, A; Tellez, AB; Turnbull, B; Vaughn, D; Waliki, M | 1 |
| Deininger, E; Moch, H; Razafinjatovo, CF; Rechsteiner, M; Schraml, P; Stiehl, D | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Fujita, M; Koma, H; Nakamura, T; Okamura, N; Yagami, T; Yamamori, M; Yamamoto, Y | 1 |
| Ansell, W; Nystrom, M; Oliver, RT; Shamash, J; Steele, JP; Wilson, P | 1 |
| Chevreau, C; Culine, S; Droz, JP; Escudier, B; Fizazi, K; Mery-Mignard, D; Rolland, F | 1 |
| Ansell, W; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Asano, T; Hayakawa, M; Horiguchi, A; Ito, K; Kakizoe, T; Koizumi, F; Matsumura, Y; Sumitomo, M | 1 |
| Ilson, DH; Law, TM; Motzer, RJ | 1 |
| Kojima, Y; Miki, T; Nishimura, K; Nonomura, N; Okuyama, A; Sawada, M; Takaha, N | 1 |
1 review(s) available for camptothecin and Carcinoma, Renal Cell
| Article | Year |
|---|---|
TroVax in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembryonic Antigen; Carcinoma, Renal Cell; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Leucovorin; Membrane Glycoproteins; Organoplatinum Compounds; Vaccination; Vaccines, DNA; Vaccinia virus | 2014 |
5 trial(s) available for camptothecin and Carcinoma, Renal Cell
| Article | Year |
|---|---|
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Renal Cell; Cyclodextrins; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lymphatic Metastasis; Male; Prognosis; Standard of Care; Survival Rate | 2017 |
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Renal Cell; Cyclodextrins; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nanoparticles; Protein Kinase Inhibitors | 2016 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival; Treatment Outcome | 2003 |
A phase II study of irinotecan in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Phase II trial of topotecan in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan | 1994 |
8 other study(ies) available for camptothecin and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Kidney Pelvis; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Treatment Outcome; Ureterostomy; Urologic Neoplasms; Urothelium | 2017 |
Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Topics: Apigenin; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Camptothecin; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; DNA Damage; Endothelin-1; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Protein Biosynthesis; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2013 |
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Elongin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Mutation, Missense; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sunitinib; Transfection; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
15-Deoxy-Δ12,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Humans; Kidney Neoplasms; PPAR gamma; Prostaglandin D2 | 2011 |
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cytokines; Drug Resistance, Neoplasm; Humans; Irinotecan; Kidney Neoplasms; Mitomycin; Neoplasm Metastasis; Prognosis | 2005 |
Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Micelles; Prodrugs; Xenograft Model Antitumor Assays | 2008 |
Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Humans; Irinotecan; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |